Results 181 to 190 of about 5,863 (219)

Safety and immunogenicity of MF59-adjuvanted influenza vaccine in the elderly

Vaccine, 1999
Safety and immunogenicity of the influenza vaccine adjuvanted with MF59 (FLUAD) were compared to those of a non adjuvanted subunit vaccine in elderly subjects during three consecutive influenza seasons. Geometric mean titres and proportions of subjects with either a > or = four-fold increase in antibody titres or with an HI titre > or = 128 after ...
S, De Donato, D, Granoff, M, Minutello, G, Lecchi, M, Faccini, M, Agnello, F, Senatore, P, Verweij, B, Fritzell, A, Podda   +9 more
openaire   +2 more sources

The adjuvanted influenza vaccines with novel adjuvants: experience with the MF59-adjuvanted vaccine

Vaccine, 2001
Elderly people and subjects with underlying chronic diseases are at increased risk for influenza and related complications. Conventional influenza vaccines provide only limited protection in the elderly population. In order to enhance the immune response to influenza vaccines, several adjuvants have been evaluated. Among these, an oil in water adjuvant
openaire   +2 more sources

Exposure to MF59-adjuvanted influenza vaccines during pregnancy—A retrospective analysis

Vaccine, 2010
Pregnant women are at increased risk for complications and death associated with pandemic H1N1 influenza infection and they are prioritized for vaccination by public health authorities. Few data are available on the safety of adjuvants as components of pandemic vaccines that could be given systematically to pregnant women.
Theodore, Tsai, Moe H, Kyaw, Deborah, Novicki, Pantaleo, Nacci, Saroj, Rai, Ralf, Clemens   +5 more
openaire   +2 more sources

The mechanism of action of MF59 – An innately attractive adjuvant formulation

Vaccine, 2012
MF59 is a safe and effective vaccine adjuvant which was originally approved to be included in a licensed influenza vaccine to be used in the elderly in Europe in 1997. The MF59 adjuvanted influenza vaccine (Fluad™) is now licensed in more than 20 countries worldwide and more than 85 million doses have been administered.
D T, O'Hagan, G S, Ott, E, De Gregorio, A, Seubert   +3 more
openaire   +2 more sources

Safety of MF59-adjuvanted versus non-adjuvanted influenza vaccines in children and adolescents: An integrated analysis

Vaccine, 2010
We reviewed the safety of MF59-adjuvanted versus non-adjuvanted influenza vaccines in children and adolescents (aged 6 months-18 years) in an integrated analysis of all pediatric trials evaluating MF59-containing influenza vaccines completed to date (5 trials).
Steven, Black, Giovanni, Della Cioppa, Anne, Malfroot, Pantaleo, Nacci, Uwe, Nicolay, Michele, Pellegrini, Etienne, Sokal, André, Vertruyen   +7 more
openaire   +2 more sources

Distribution of adjuvant MF59 and antigen gD2 after intramuscular injection in mice

Vaccine, 1999
MF59, which is an adjuvant approved for human use, typically elicits higher antibody titers than alum when used in combination with a variety of recombinant and natural subunit antigens. The mechanisms responsible for the adjuvant action of MF59 are not fully understood.
M, Dupuis, D M, McDonald, G, Ott
openaire   +2 more sources

Enhanced Immunogenicity of Seasonal Influenza Vaccines in Young Children Using MF59 Adjuvant

Pediatric Infectious Disease Journal, 2009
Children have high morbidity and hospitalization rates from seasonal influenza. Meta-analyses suggest that conventional inactivated influenza vaccines are of low efficacy in young children, making vaccines that induce greater and broader immune protection in this vulnerable population a medical priority.
Timo, Vesikari, Michele, Pellegrini, Aino, Karvonen, Nicola, Groth, Astrid, Borkowski, Derek T, O'Hagan, Audino, Podda   +6 more
openaire   +2 more sources

Immunogenicity and Safety of MF59-Adjuvanted H5N1 Influenza Vaccine From Infancy to Adolescence

Pediatrics, 2010
OBJECTIVE: This study evaluated the immunogenicity, safety, and tolerability of a MF59-adjuvanted H5N1 vaccine in a population 6 months through 17 years of age. METHODS: Healthy subjects 6 to <36 months, 3 to <9 months, and 9 to & ...
VESIKARI, T., KARVONEN, A., TILMAN, S., BORKOWSKI, A., MONTOMOLI, E., BANZHOFF, A., CLEMENS, R.   +6 more
openaire   +3 more sources

ChemInform Abstract: MF59® Adjuvanted Seasonal and Pandemic Influenza Vaccines

ChemInform, 2012
AbstractReview: 58 refs.
openaire   +1 more source

Antibody induction by virosomal, MF59-adjuvanted, or conventional influenza vaccines in the elderly

Vaccine, 2007
In a randomized, observer-blind, three-arm, parallel group, multi-centre trial including 386 elderly subjects in four countries, the immunogenicity and safety was studied of three different trivalent inactivated surface antigen (subunit) influenza vaccine types: a conventional subunit influenza vaccine (SIV, brand: Influvac and two newer vaccines: a ...
Iris, de Bruijn, Ingo, Meyer, Lisya, Gerez, Jos, Nauta, Katinka, Giezeman, Bram, Palache   +5 more
openaire   +2 more sources